Biocon Biologics' insulin manufacturing facility in Malaysia completes USFDA (PAI) Inspection

At the conclusion of the inspection, the agency has issued a Form 483 with a total of 6 observations.

from India Infoline News Service https://ift.tt/2XOeVVB